Coya Therapeutics Inc. Common Stock

Coya Therapeutics Inc. a clinical-stage biotechnology company engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities such as Treg-enhancing biologics Treg-derived exosomes and autologous Treg cell therapy. It is developing COYA 101 an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301 a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302 a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201 an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative autoimmune and metabolic diseases; and COYA 206 an antigen directed Treg-derived exosome product candidate which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston Texas.